Prof. Dr. rer. nat. Holger Kalthoff, Founding Director of the Institute for Experimental Cancer Research.
He represents research groups active in clinical aspects of the development
of anti-cancer drugs in the AB and contributes the position of end user and
Dr. Eckhard G. Günther, Head of Drug Discovery at Zentaris AG since January 2001.
Dr. Günther has more than 15 years of experience in the biotechnology and
biopharmaceutical industries, as a researcher as well as a manager. He
represents members of pharmaceutical companies in the AB.
Dr. Ronald Frank, coordinator of EU-OPENSCREEN.
EU-OPENSCREEN, the European Infrastructure of Open Screening Platforms
for Chemical Biology. Dr. Frank represents European screening activities and
therefore players active in the search and development of anti-cancer drugs
in the AB. He provides European aspects and assay issues.
Dr. Peter Hylands, his special research interest was always in natural products in medicine.
He joined the commercial world in 1988 as Director of Chemistry and then
Research Director of biopharmaceutical companies in the UK and the USA.
He has consulted for the United Nations and Commonwealth Science Council.
He is currently Head of the Institute of Pharmaceutical Science, King’s College London.
His current research emphasises the application of chemometrics and emerging
biotechnologies to the problems of standardisation and quality control of plant medicines.